Yiduoli: the industrial layout of "bio medicine + bio manufacturing" has been basically completed

Yiduoli is the first enzyme preparation listed company in China and the largest enzyme preparation manufacturer in Asia In 2015, the company entered the field of steroid hormone medicine through merger and acquisition Since its development, it has gradually formed a "one body, two wings and four dimensions" strategic pattern with modern bioengineering as the main body, biopharmaceutical and biological manufacturing as the two wings, and biological drugs, biological enzyme preparations, plant extracts and functional feed additives as the four dimensions, forming an industrial linkage advantage "With the completion of industrial layout, the company will gradually enter the stage of project implementation and flowering, hoping to usher in a new growth period." Recently, a reporter from China Securities News visited Yiduoli Chen shaomei, chairman of the company, said that in the future, the company will continue to provide overall biotechnology solutions for industrial enterprises, and is committed to becoming the world's leading biotechnology enterprise Since the expansion of steroidal drugs went on the market in 2014, the scale of its development has nearly quadrupled, and it has become a highly competitive enterprise in China's steroidal drug industry This is mainly due to the company's acquisition of Henan Lihua pharmaceutical and Hunan Xinhe new biology in 2015, and its strategic entry into the field of biomedicine, expanding from enzyme products to the research, development, production and sales of steroid hormone intermediates, APIs and preparations Then, the proportion of Yiduoli's biomedical business scale in the main business keeps increasing As of June 30, 2019, the operating revenue of Yiduoli's biomedical business reached 442 million yuan, accounting for 51.77% of the company's total operating revenue Chen shaomei introduced that steroids play an important role in the pharmaceutical industry and are the second largest category of drugs after antibiotics As a widely used drug in various clinical departments, the market demand for steroid pharmaceutical products keeps growing According to chinapharma.com, in 2016, the global sales of steroids exceeded US $100 billion, which is now the second largest category of chemicals after antibiotics At the same time, the Research Report of Haitong Securities (15.240, 0.00, 0.00%) shows that since the 1990s, the sales volume of steroids in the international market has increased by 10% - 15% every year Based on this, the global sales volume of steroids in 2018 is estimated to be about US $120-130 billion The sustained growth of market demand and sales scale of steroid hormone drugs will promote the long-term stable growth of steroid intermediate and API industry "The company's steroid hormone intermediates and API products already have a certain market scale and competitiveness in China, and will use this momentum to expand the category." Chen shaomei revealed that, first, we should comprehensively carry out relevant marketing channels and brand building work for large varieties of economic animal medicine and pet medicine preparations; second, we should expand to the direction of human medicine preparations Currently, the company has a small number of preparations, which will increase in the future "In terms of animal medicine, the company has rich approval documents for hand products, and will continue to develop new varieties of pet medicine On the whole, the growth rate of pet drugs is higher than the average growth rate of the pharmaceutical industry Most pet drugs in China are imported, and there is a large space for import substitution We will speed up the layout of pet drugs from the aspects of technical reserves, certificate application and market development " Chen shaomei further said After years of operation, Yiduoli has developed into the largest feed enzyme preparation Enterprise in Asia Based on its leading scale, the company has gradually established its advantages in management Since 2019, the impact of CSFV epidemic in Africa is still continuing, and there is no effective vaccine for prevention and control, which has a significant impact on the aquaculture industry and its upstream feed and feed additive industries In the face of this situation, Yiduoli responded quickly, adjusted the product structure in time, and realized the steady growth of business against the trend The semi annual report of 2019 shows that the gross profit margin of feed enzyme business of the company is as high as 61.96%, the revenue of feed enzyme products is up by 18.44% year on year, and the gross profit margin is up by 4.34% year on year "It is mainly due to the transformation and adjustment of the company to poultry, aquatic products, ruminant and other fields, as well as the optimization of marketing channels that the company has achieved good results." Chen shaomei told reporters that the outbreak of CSFV may affect the dietary structure of residents, and is optimistic about the substitution effect of ruminants The company has made a positive layout in this regard In the future, the company will continue to optimize the product structure and marketing channels, and at the same time, it will launch a feeding non resistant product program to find new opportunities for Industry Development in the crisis In addition to the feed industry, the company has entered many industries, such as energy, food, textile, papermaking and so on, and has become the most widely used biological enzyme preparation Enterprise in the industry In the future, environmental protection enzyme and cleaning enzyme are the promising development direction of the company As an important part of biotechnological solutions, lay out the feed antibiotic alternative market, and "antibiotic free" (antibiotic free) additives "is another business that will be focused on in the future At the end of 2018, the company acquired Changsha Shiwei technology, cut into medicinal plant extract, and used plant extract + biological enzyme preparation as the "alternative anti" (instead of antibiotics) scheme, which has high competitiveness in technology and cost According to Announcement No 194 issued by the Ministry of agriculture and rural areas, from January 1, 2020, all growth promoting drug feed additive varieties, except for traditional Chinese medicine, will be withdrawn, and the production of veterinary drug manufacturers will be stopped, and the import of veterinary drug agents will stop importing corresponding veterinary drug products; from July 1, 2020, the production of feed manufacturers containing growth promoting drug feed additives (excluding traditional Chinese Medicine) will be stopped Commercial feed "In fact, the company did not start to take measures in the field of no resistance until the above documents were issued Europe and the United States began to prohibit resistance more than ten years ago We have also thought about the product layout after the prohibition for many years." Chen shaomei said that in order to meet the coming era of "no resistance", the company released the product portfolio of no resistance breeding in July this year - boluohui + glucose oxidase Boluohui is the first patent product of natural plant medicine feed additive that can be added and used for a long time independently developed in China, filling the gap of domestic natural plant medicine feed additive With the implementation of "no resistance" breeding, the market prospect of "plant substitute resistance" is broad.